ethyl 8-chlorooctanoate

We are ethyl 8-chlorooctanoate CAS:105484-55-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: ethyl 8-chlorooctanoate
CAS.NO:105484-55-7
Molecular Formula: ：C10H19ClO2
Molecular Weight:206.71000

Synonyms:
8-CHLOROOCTANOIC ACID ETHYL ESTER
ethyl-8-chlorooctanoate
Octanoic acid,8-chloro-,ethyl ester

Physical and Chemical Properties:
Density:0.991g/cm3
Boiling point:251.5ºC at 760 mmHg
Melting point:/
Flash point: 107.5ºC
Refractive index: 1.44

Specification:
Appearance:White  powder
Purity:≥98.0%
Moisture Content: 0.25%
Impurity: 0.3%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: For pharmaceutical intermediates.

Related News: The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy.(S,S)-2,8-Diazabicyclo[4,3,0]Nonane The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy.Dipropylamine By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.1-(2-amino-4-methoxy-3-methylphenyl)ethanone CAS:912347-94-5 According to statistics from the Price Supervision and Competition Bureau of the National Development and Reform Commission, China can produce more than 1,500 kinds of bulk drugs, with a total output of one million tons and an export volume of more than 60%. It has become the world’s second largest drug substance after the United States. Country of manufacture and largest exporter.Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,” said Mark Corbett, EVP, Inceptua Medicines Access.